1
|
Whitley CA, Ellis BG, Triantafyllou A, Gunning PJ, Gardner P, Barrett SD, Shaw RJ, Smith CI, Weightman P, Risk JM. Prediction of prognosis in oral squamous cell carcinoma using infrared microspectroscopy. Cancer Med 2024; 13:e7094. [PMID: 38468595 DOI: 10.1002/cam4.7094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 11/14/2023] [Accepted: 02/28/2024] [Indexed: 03/13/2024] Open
Abstract
BACKGROUND Estimation of prognosis of oral squamous cell carcinoma (OSCC) is inaccurate prior to surgery, only being effected following subsequent pathological analysis of the primary tumour and excised lymph nodes. Consequently, a proportion of patients are overtreated, with an increase in morbidity, or undertreated, with inadequate margins and risk of recurrence. We hypothesise that it is possible to accurately characterise clinical outcomes from infrared spectra arising from diagnostic biopsies. In this first step, we correlate survival with IR spectra derived from the primary tumour. METHODS Infrared spectra were collected from tumour tissue from 29 patients with OSCC and subject to classification modelling. RESULTS The model had a median AUROC of 0.89 with regard to prognosis, a median specificity of 0.83, and a hazard ratio of 6.29 in univariate Cox proportional hazard modelling. CONCLUSION The data suggest that FTIR spectra may be a useful early biomarker of prognosis in OSCC.
Collapse
Affiliation(s)
- Conor A Whitley
- Department of Physics, University of Liverpool, Liverpool, UK
| | - Barnaby G Ellis
- Department of Physics, University of Liverpool, Liverpool, UK
| | - Asterios Triantafyllou
- Department of Pathology, Liverpool Clinical Laboratories, University of Liverpool, Liverpool, UK
| | - Philip J Gunning
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Peter Gardner
- Department of Chemical Engineering, The University of Manchester, Manchester, UK
| | - Steve D Barrett
- Department of Physics, University of Liverpool, Liverpool, UK
| | - Richard J Shaw
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
- Regional Maxillofacial Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
| | | | - Peter Weightman
- Department of Physics, University of Liverpool, Liverpool, UK
| | - Janet M Risk
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| |
Collapse
|
2
|
Bruschini R, Maffini F, Chiesa F, Lepanto D, De Berardinis R, Chu F, Tagliabue M, Giugliano G, Ansarin M. Oral cancer: changing the aim of the biopsy in the age of precision medicine. A review. ACTA ACUST UNITED AC 2021; 41:108-119. [PMID: 34028455 PMCID: PMC8142729 DOI: 10.14639/0392-100x-n1056] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 02/03/2021] [Indexed: 01/15/2023]
Abstract
Oral cancer is a heterogeneous disease that develops through a complex, multi-step process. Precision medicine should help to better understand its molecular basis, integrate traditional classifications and have a positive impact on cancer management. To apply this information in clinical practice, we need to define its histology and identify biomarkers expressed by the tumour that provide useful information for planning tailored treatment. The most reliable information currently derives from evaluation of biomarkers on post-operative samples. To plan personalised treatment, oncologists need to assess these markers on biopsy samples. We reviewed the recent literature and identified 6 of 184 publications that compared markers measured on biopsy and post-operative samples or assessed their predictivity for the development of lymph node metastases. Data from these studies suggest that markers measured on biopsy samples can provide useful indications for tailoring treatments. However, due to their heterogeneity and low level of evidence, these results need to be confirmed by clinical studies on a large population to standardise and validate biomarkers in biopsies and to assess their reliability in other diagnostic mini-invasive procedures such as radiomics and liquid biopsy.
Collapse
Affiliation(s)
- Roberto Bruschini
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| | - Fausto Maffini
- Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy
| | - Fausto Chiesa
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| | - Daniela Lepanto
- Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy
| | - Rita De Berardinis
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| | - Francesco Chu
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| | - Marta Tagliabue
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| | - Gioacchino Giugliano
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| | - Mohssen Ansarin
- Division of Otolaryngology and Head & Neck Surgery, European Institute of Oncology IRCCS, Milan, Italy
| |
Collapse
|
3
|
Bello IO, Wennerstrand PM, Suleymanova I, Siponen M, Qannam A, Nieminen P, Leivo I, Almangush A, Salo T. Biopsy quality is essential for preoperative prognostication in oral tongue cancer. APMIS 2020; 129:118-127. [PMID: 33320967 DOI: 10.1111/apm.13104] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 12/06/2020] [Indexed: 12/19/2022]
Abstract
A role for incisional biopsy in preoperative prognostication is increasingly being advocated in oral tongue squamous cell carcinomas (OTSCC). Biopsies at two locations were compared, and prognostic factors in biopsies and their corresponding resections were evaluated. A total of 138 OTSCC biopsy slides from Finland and Saudi Arabia were compared for size (horizontal and vertical) and invasive front. The Finnish cases were assessed for tumor stroma ratio (TSR) and tumor-infiltrating lymphocytes (TILs) using light microscopy and digital image analysis assessment and compared. Furthermore, TSR, TILs, and previously analyzed budding and depth of invasion (BD) score in biopsies were compared with their evaluation in the corresponding resections. Fifty-nine percent of Finnish and 42% of Saudi Arabian biopsies were ≥ 5 mm deep, while 98% of Saudi Arabian and 76% of Finnish biopsies were ≥ 5 mm wide. Assessment of invasion front was possible in 72% of Finnish in comparison with 40% of Saudi Arabian biopsies. There was 86.8% agreement between TSR and 75% agreement between TIL evaluation using light microscopy and digital assessment. Significant agreement was obtained on comparing the TSR (p = 0.04) and BD (p < 0.001) values in biopsies and resections. Biopsies of ≥ 5 mm depth from representative OTSCC areas are essential for prognostic information. Clinical pathologists are advised to assess BD score and TSR for prognostic features in such biopsies.
Collapse
Affiliation(s)
- Ibrahim O Bello
- Department of Oral Medicine and Diagnostic Sciences, King Saud University, Riyadh, Saudi Arabia.,Department of Pathology, University of Helsinki, Helsinki, Finland
| | | | - Ilida Suleymanova
- Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Maria Siponen
- Institute of Dentistry, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.,Oral Health Teaching Clinic and Department of Oral and Maxillofacial Diseases, Kuopio University Hospital, Kuopio, Finland
| | - Ahmed Qannam
- Department of Oral Medicine and Diagnostic Sciences, King Saud University, Riyadh, Saudi Arabia
| | - Pentti Nieminen
- Medical Informatics and Data Analysis Research Group, University of Oulu, Oulu, Finland
| | - Ilmo Leivo
- Institute of Biomedicine, Pathology, University of Turku, Turku, Finland
| | - Alhadi Almangush
- Department of Pathology, University of Helsinki, Helsinki, Finland.,Institute of Biomedicine, Pathology, University of Turku, Turku, Finland.,Faculty of Dentistry, University of Misurata, Misurata, Libya
| | - Tuula Salo
- Department of Pathology, University of Helsinki, Helsinki, Finland.,Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.,Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
| |
Collapse
|
4
|
Leite CF, Silva KDD, Horta MCR, de Aguiar MCF. Can morphological features evaluated in oral cancer biopsies influence in decision-making? A preliminary study. Pathol Res Pract 2020; 216:153138. [PMID: 32853958 DOI: 10.1016/j.prp.2020.153138] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 07/20/2020] [Accepted: 07/23/2020] [Indexed: 11/16/2022]
Abstract
Tumor budding (TB) is a promising prognostic marker in many cancers including oral squamous cell carcinoma. The evaluation of TB in preoperative diagnostic biopsies has been proven be possible; therefore, the association of TB with other morphological features can represent an important aid in the previous treatment decision. This study aims to evaluate TB in oral squamous cell carcinoma (OSCC) biopsies, assessing its association with other morphological characteristics of the sample. A total of 56 cases of OSCC were investigated. In hematoxylin and eosin-stained slides, morphological features including histopathological grading and mode of invasion were evaluated in the deep invasive front. Moreover, immunohistochemistry was performed with anti-multi-cytokeratin antibody helping in the identification of TB, which was graded as low-intensity or no TB and high-intensity TB. Descriptive and bivariate analyses were performed, and the level of significance was set at 5%. The tongue was the most-affected site with 29 (51.7 %) tumors. The predominant mode of invasion (27-48.2 %) was by groups of neoplastic cells without clear boundaries. Of the cases investigated, 37 (66.1 %) were high-intensity TB, which was associated with the mode of invasion of the tumors (p < 0.05). All cases with the worst mode of invasion showed high-intensity TB. Preliminary results showed the potential of morphological features, such as TB and mode of invasion, evaluated in diagnostic specimens of OSCC, aiding in the treatment decision to select patients who could benefit from more-aggressive treatments.
Collapse
Affiliation(s)
- Camila Ferreira Leite
- Department of Oral Pathology and Surgery, School of Dentistry, Universidade Federal De Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
| | - Karine Duarte da Silva
- Department of Oral Pathology and Surgery, School of Dentistry, Universidade Federal De Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
| | - Martinho Campolina Rebello Horta
- Oral Pathology Section, School of Dentistry, Pontifical Catholic University of Minas Gerais (PUC Minas), Belo Horizonte, MG, Brazil.
| | - Maria Cássia Ferreira de Aguiar
- Department of Oral Pathology and Surgery, School of Dentistry, Universidade Federal De Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
| |
Collapse
|
6
|
Müller S, Boy SC, Day TA, Magliocca KR, Richardson MS, Sloan P, Tilakaratne WM, Zain RB, Thompson LDR. Data Set for the Reporting of Oral Cavity Carcinomas: Explanations and Recommendations of the Guidelines From the International Collaboration of Cancer Reporting. Arch Pathol Lab Med 2018; 143:439-446. [PMID: 30500296 DOI: 10.5858/arpa.2018-0411-sa] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The International Collaboration on Cancer Reporting is a nonprofit organization whose goal is to develop evidence-based, internationally agreed-upon standardized data sets for each cancer site for use throughout the world. Providing global standardization of pathology tumor classification, staging, and other reporting elements will lead to the objective of improved patient management and enhanced epidemiologic research. Carcinomas of the oral cavity continue to represent a significant oncologic management burden, especially as changes in alcohol and tobacco use on a global scale contribute to tumor development. Separation of oral cavity carcinomas from oropharyngeal tumors is also important, as management and outcome are quite different when human papillomavirus association is taken into consideration. Topics such as tumor thickness versus depth of invasion, pattern of invasive front, extent and size of perineural invasion, and margin assessment all contribute to accurate classification and staging of tumors. This review focuses on the data set developed for Carcinomas of the Oral Cavity Histopathology Reporting Guide, with discussion of the key elements developed for inclusion.
Collapse
Affiliation(s)
- Susan Müller
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Sonja C Boy
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Terrence A Day
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Kelly R Magliocca
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Mary S Richardson
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Philip Sloan
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Wanninayake M Tilakaratne
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Rosnah B Zain
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| | - Lester D R Thompson
- From Atlanta Oral Pathology, Decatur, Georgia (Dr Müller); Lancet Laboratories, Pretoria, South Africa (Dr Boy); the Departments of Otolaryngology-Head and Neck Surgery (Dr Day) and Pathology and Laboratory Medicine (Dr Richardson), Medical University of South Carolina, Charleston; the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Magliocca); the Department of Cellular Pathology, Newcastle University, Newcastle upon Tyne, United Kingdom (Dr Sloan); the Department of Oral Pathology, University of Peradeniya, Sri Lanka (Dr Tilakaratne); the Department of Oral Pathology, Faculty of Dentistry, MAHSA University, Selangor, Jalan, Malaysia (Dr Zain); and the Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, California (Dr Thompson)
| |
Collapse
|